Drugs / KBP-5209
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02442414 | Apr 2015 → Nov 2019 | — | Sihuan Pharmaceutical Holdings Group Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KBP-5209 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02442414 ↗ |
| Route | Oral | “KBP-5209 administered orally once daily (QD)” NCT02442414 ↗ |